Evofem Biosciences Inc. (NASDAQ: EVFM) is 63.90% higher on its value in year-to-date trading and has touched a low of $1.91 and a high of $6.87 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The EVFM stock was last observed hovering at around $3.84 in the last trading session, with the day’s gains setting it 0.11% off its average median price target of $6.50 for the next 12 months. It is also 64.09% off the consensus price target high of $11.00 offered by 4 analysts, but current levels are -31.67% lower than the price target low of $3.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $3.95, the stock is 1.78% and 28.19% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.52 million and changing 2.86% at the moment leaves the stock 32.54% off its SMA200. EVFM registered -35.14% loss for a year compared to 6-month loss of 26.20%. The firm has a 50-day simple moving average (SMA 50) of $3.4303 and a 200-day simple moving average (SMA200) of $2.7568.
The stock witnessed a 50.19% gain in the last 1 month and extending the period to 3 months gives it a 72.49%, and is -3.42% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.56% over the week and 10.96% over the month.
Evofem Biosciences Inc. (EVFM) has around 53 employees, a market worth around $332.63M and $0.30M in sales. Distance from 52-week low is 106.81% and -42.50% from its 52-week high.
Evofem Biosciences Inc. (EVFM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Evofem Biosciences Inc. (EVFM) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Evofem Biosciences Inc. is expected to release its quarterly report on 05/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.36 with sales reaching $1.69M over the same period.The EPS is expected to grow by 65.40% this year.
Evofem Biosciences Inc. (EVFM) Top Institutional Holders
135 institutions hold shares in Evofem Biosciences Inc. (EVFM), with 1.34M shares held by insiders accounting for 1.65% while institutional investors hold 45.75% of the company’s shares. The shares outstanding are 81.21M, and float is at 78.84M with Short Float at 11.97%. Institutions hold 45.00% of the Float.
The top institutional shareholder in the company is Invesco Ltd. with over 12.7 million shares valued at $30.61 million. The investor’s holdings represent 15.62% of the EVFM Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.21 million shares valued at $12.56 million to account for 6.41% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.6 million shares representing 4.42% and valued at over $8.67 million, while Heartland Advisors Inc. holds 3.16% of the shares totaling 2.57 million with a market value of $6.2 million.
Evofem Biosciences Inc. (EVFM) Insider Activity
A total of 10 insider transactions have happened at Evofem Biosciences Inc. (EVFM) in the last six months, with sales accounting for 1 and purchases happening 9 times. The most recent transaction is an insider purchase by File Justin J., the company’s Chief Financial Officer. SEC filings show that File Justin J. bought 7,760 shares of the company’s common stock on Nov 17 at a price of $2.17 per share for a total of $16839.0. Following the purchase, the insider now owns 0.26 million shares.
Evofem Biosciences Inc. disclosed in a document filed with the SEC on Nov 17 that Fitzpatrick Alexander A (General Counsel and Secretary) bought a total of 9,090 shares of the company’s common stock. The trade occurred on Nov 17 and was made at $2.20 per share for $19998.0. Following the transaction, the insider now directly holds 0.14 million shares of the EVFM stock.
Still, SEC filings show that on Sep 11, Barrans Russell (Chief Commercial Officer) acquired 3,000 shares at an average price of $2.08 for $6240.0. The insider now directly holds 279,052 shares of Evofem Biosciences Inc. (EVFM).